Company Overview

Onyx Biotec Limited was incorporated as 'Onyx Biotec Private Limited' on May 13, 2005. It later converted into a Public Limited company, changing its name to 'Onyx Biotec Limited' on July 23, 2024. The company has nearly two decades of experience, establishing itself as a specialized pharmaceutical manufacturer in the sterile pharmaceutical products segment.

Onyx Biotec is associated with the healthcare segment and supplies sterile pharmaceutical products to major corporations. It manufactures Sterile Water for Injections and operates as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrup for both Indian and overseas markets. The company provides end-to-end product development and manufacturing solutions, including preparation and filing of regulatory dossiers globally.

Business Operations and Manufacturing

Onyx Biotec began its pharmaceutical operations in 2010 with sterile water for injections, boasting an initial capacity of 2 lac units per day. Since then, it has expanded into manufacturing sterile water ampoules, dry injections, and dry syrups for major pharmaceutical corporations.

The company operates from two manufacturing facilities in Solan, Himachal Pradesh.

- Unit I: Daily production capacity of 638,889 units of sterile Water for Injections.

- Unit II: Daily production capacity of 40,000 units of dry powder injections and 26,667 units of dry syrup per day (in a single shift).

This robust infrastructure supports Onyx Biotec's ability to serve a diverse client base across India and international markets. Its core business includes supplying sterile injections and providing contract manufacturing services to leading pharmaceutical brands such as Hetero Healthcare and Sun Pharmaceuticals. The company holds certifications like ISO 9001:2015 and ISO 14001:2015, underscoring its commitment to quality and environmental standards. Onyx Biotec's impressive client list of over 100 firms highlights its market reach and reliability.

Stock Market Performance and Valuation

Onyx Biotec Ltd has a market capitalization of ₹91 Cr as of April 15, 2025. Classified as a Small Cap company, its stock trades on the NSE SME segment under the symbol ONYX, following its successful IPO in November 2024.

- PE Ratio: 29.94 (as of Apr 15, 2025)

- PB Ratio: 0.60 (as of Apr 15, 2025)

- 52-Week High: ₹97.45

- 52-Week Low: ₹50.00

- All-Time High: ₹97.45 (Jan 2, 2025)

- All-Time Low: ₹45.00 (May 30, 2025 - _Note: This date seems to be in the future, likely a typo_)

Financial Performance and Key Metrics

Onyx Biotec has demonstrated significant revenue growth in recent years, reflecting operational efficiency and market expansion.

- Operating Revenue (TTM): ₹147.27 Cr

- Annual Revenue Growth: 36% (outstanding)

- Pre-tax Margin: 8% (okay)

- ROE: 12% (good)

- Revenue Growth (YoY): Increased by 35.99% for the financial year ending March 31, 2024, compared to March 31, 2023.

- Profit After Tax (PAT) Growth (YoY): Rose by 64.35% for the financial year ending March 31, 2024, compared to March 31, 2023.

- Recent Profit Update (May 28, 2025): Reported profit of ₹4.95 Cr, up from ₹3.63 Cr, with IPO proceeds utilized as per objectives.

- TTM Profit After Tax: ₹3 Cr

- Debt to Equity Ratio: 95% (slightly higher)

- Total Asset Value: ₹74 Cr (as on 31-Mar-24)

IPO and Recent Corporate Developments

Onyx Biotec's Initial Public Offering (IPO) was a book-building issue of ₹29.34 crores, comprising entirely a fresh issue of 48.10 lakh shares. The IPO bidding period was from November 13 to November 18, 2024, with allotment finalized on November 19, 2024. The shares were listed on NSE SME on November 22, 2024, initially trading at ₹56.75, a discount of 6.97% from the issue price of ₹61.

Prior to the IPO, on November 12, 2024, the company raised ₹8.33 crore from anchor investors by allotting 13.66 lakh shares at ₹61 per share to 3 anchor investors. The IPO funds are allocated towards capacity expansion, upgrading manufacturing facilities, and general corporate purposes.

Leadership and Management

- Chairman: (Name not provided in source text)

- Managing Director: Sanjay Jain

- Promoters: Sanjay Jain, Naresh Kumar, and Fateh Pal Singh.

The experienced leadership team brings extensive pharmaceutical industry expertise to guide the company's strategic direction and operational excellence.

Industry Position and Competitive Landscape

Onyx Biotec Ltd competes with major pharmaceutical companies such as Sun Pharmaceutical Industries Ltd, Divi's Laboratories Ltd, Cipla Ltd, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Dr. Reddy's Laboratories Ltd, and Lupin Ltd.

Within the contract manufacturing space, particularly for sterile water for injections and dry powder formulations, Onyx Biotec has carved out a niche. The company operates in a specialized segment requiring high-quality manufacturing standards and strict regulatory compliance. While the market for sterile water, dry powder, and syrup products is competitive and fragmented, Onyx Biotec's consistent client relationships and quality certifications provide a competitive edge in securing long-term contracts.

The company's business model focuses on leveraging the growing trend of pharmaceutical companies outsourcing manufacturing. This provides stable revenue streams and allows Onyx Biotec to benefit from the overall growth of India's pharmaceutical sector. Its quality credentials and established client base position it well to capitalize on increasing demand for sterile pharmaceutical products both domestically and internationally. The company has noted inconsistency in its top lines and fluctuating bottom lines in reported periods, but its specialization and client focus remain key strengths.